Thomas Fuller | SOPA Photos | Lightrocket | Getty Photos
UniQure must run one other research to show that its gene remedy “really helps folks with Huntington’s illness,” a senior U.S. Meals and Drug Administration official stated on a name with reporters Thursday.
The official, who requested anonymity earlier than discussing delicate info, confirmed the company has requested the corporate to run a placebo managed trial of its therapy, which is run straight into the mind. UniQure has stated that kind of research is not moral as a result of it might require placing folks beneath common anesthesia for hours, a characterization the official disputed.
“So what is absolutely occurring? UniQure is the newest firm to make a failed remedy for Huntington’s sufferers,” the official stated. “They doubtless acknowledge or perceive at some deep stage that their trial failed years in the past, and as an alternative of doing the best factor and operating the right scientific research, UniQure is performing a distorted or manipulated comparability within the thoughts of FDA.”
The feedback mark the newest improvement in a messy public spat between UniQure and the FDA, and as the company comes beneath fireplace for various latest drug approval software rejections, together with some the place corporations have accused it of going again on earlier steerage. FDA Commissioner Marty Makary in an interview with CNBC’s Becky Fast final week seemingly criticized UniQure’s gene remedy for Huntington’s illness. Makary did not identify UniQure however described its therapy.
UniQure then accused the FDA of reversing its stance that the corporate’s scientific trial knowledge could be ample to hunt approval. UniQure’s research used an outdoor database to measure how sufferers with Huntington’s illness may decline with out therapy, referred to as an exterior management. UniQure has stated it would not be possible to run a real randomized, double-blind placebo-controlled research, thought-about the gold commonplace, as a result of it would not be moral to make folks bear a sham hours-long mind surgical procedure.
The FDA official stated the company “by no means agreed to just accept this distorted comparability” and the FDA “by no means makes such assurances.” As an alternative, the “FDA will at all times say, ‘Properly, now we have to see the info after we get it.'”
UniQure did not instantly remark.
The corporate’s inventory rose greater than 10% on Thursday and has fallen 58% this 12 months as of Thursday afternoon.